E
Tonix Pharmaceuticals Holding Corp. TNXP
$15.14 -$2.35-13.44%
Recommendation
Sell
Prev Close
$17.49
Volume
634,974
Avg Vol (90D)
1,687,638
Market Cap
$112.55M
Dividend & Yield
--
52-Week Range
$6.76 - $672.00
P/E (TTM)
--
EPS (TTM)
-$2,552.08
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Pharma Frenzy: Volatility Ignites Biotech Sector
3/25/2025 - MarketBeat
Tonix Pharmaceuticals Holding (TNXP, $17.49) entered Downtrend as Momentum indicator drops below 0 level on Apr 03, 2025
4/4/2025 - Tickeron - Stocks
Tonix Pharmaceuticals Holding (TNXP, $17.39) Moving Average Convergence Divergence (MACD) Histogram turned negative on April 2, 2025
4/3/2025 - Tickeron - Stocks
Tonix Pharmaceuticals Holding (TNXP, $17.45) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2025
4/2/2025 - Tickeron - Technical Analysis
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference
4/2/2025 - Globe Newswire
Tonix Pharmaceuticals Holding (TNXP, $17.88) Stochastic Oscillator left the oversold zone on March 31, 2025
4/1/2025 - Tickeron - Technical Analysis
Tonix Pharmaceuticals Launches TONIX ONE , a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition
4/1/2025 - Globe Newswire
Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year
3/31/2025 - Accesswire
Tonix Pharmaceuticals Holding (TNXP, $26.67) RSI Indicator left the overbought zone on March 27, 2025
3/28/2025 - Tickeron - Technical Analysis
Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
3/27/2025 - Globe Newswire
Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 0.4% - Should You Sell?
3/26/2025 - MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 39.5% - Should You Buy?
3/25/2025 - MarketBeat
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia
3/24/2025 - Globe Newswire
Tonix Pharmaceuticals Holding (TNXP, $23.03) RSI Indicator left the overbought zone on March 21, 2025
3/22/2025 - Tickeron - Stocks
Tonix Pharmaceuticals Holding (TNXP, $23.03) price may drop as it broke higher Bollinger Band on Mar 21, 2025
3/22/2025 - Tickeron - Stocks
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread
3/20/2025 - Accesswire
Tonix Pharmaceuticals Holding (TNXP, $20.53) price may drop as it broke higher Bollinger Band on Mar 18, 2025
3/19/2025 - Tickeron - Stocks
Tonix Pharmaceuticals Holding (TNXP, $20.53) RSI Indicator left the overbought zone on March 18, 2025
3/19/2025 - Tickeron - Stocks
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
3/18/2025 - Globe Newswire
Tonix Pharmaceuticals secures MCDC grant to advance next-gen Mpox & Smallpox vaccine development
3/14/2025 - Proactive Investors - UK
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025
3/13/2025 - Globe Newswire
Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target
3/12/2025 - Accesswire
Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th
3/11/2025 - Globe Newswire
Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company's Single-Dose Mpox and Smallpox Vaccine Candidate
3/10/2025 - Globe Newswire
Is Tonix Pharmaceuticals the Next Biotech Breakout?
1/30/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$10.09M
EBITDA (TTM)
-$74.32M
EBIT (TTM)
-$77.74M
Net Income (TTM)
-$130.04M
Balance Sheet
Total Assets (Q)
$162.89M
Total Debt (Q)
$8.12M
Total Liabilities (Q)
$23.33M
Book Value Per Share (Q)
$31.82
Cash Flow
Cash from Operations (TTM)
-$60.93M
Cash from Investing (TTM)
-$120.00K
Cash from Financing (TTM)
$134.87M
Net Change in Cash (TTM)
$73.83M
Filings
Filing Date
Tuesday, March 18, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
0.08
7-Day Total Return
-47.36%
30-Day Total Return
65.10%
60-Day Total Return
-47.45%
90-Day Total Return
-25.86%
Year to Date Total Return
-51.78%
1-Year Total Return
-97.47%
2-Year Total Return
-99.87%
3-Year Total Return
-99.99%
5-Year Total Return
-100.00%
52-week Low
Mar 04, 2025 - $6.76
52-week High
May 17, 2024 - $672.00
Valuation
Market Cap
$112.55M - Micro Cap
Enterprise Value
$21.89M
Price/Sales (TTM)
3.92
Price/Book (Q)
0.55
Dividends and Shares
Shares Outstanding
2.26M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.tonixpharma.com
Phone Number
862 799 8599
Address
26 Main Street
Chatham, NJ 07928
Country
United States
Year Founded
2007
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate... more
NASDAQ 04/04/2025 12:38PM Eastern Quotes delayed
Weiss Ratings